Security
Zenas BioPharma, Inc. Common Stock · ZBIO
ZBIONASDAQCommon stockCurrentCIK 1953926Updated Oct 14, 2026
Name history
Zenas BioPharma (Cayman) Ltd · through Nov 15, 2022
ZBIO price & chart
Loading TradingView…
NASDAQ:ZBIO on TradingView ↗About the company
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and mi…
In the news
Zenas BioPharma to Host Virtual R&D Event ↗
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) News provided by Purcell & Lefkowitz LLP Jan 05, 2026, 09:15 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowi ↗
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) News provided by Purcell & Lefkowitz LLP Nov 20, 2025, 09:14 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Purcell & Lefkow ↗
Seeking Alpha
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve ↗
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript ↗
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 383,640,000Source | 369,968,000Source | 68,180,000Source |
| Property, Plant and Equipment, NetUSD | 34,000Source | 185,000Source | 193,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 110,641,000Source | 319,742,000Source | 56,857,000Source |
| Assets, CurrentUSD | 351,171,000Source | 355,923,000Source | 59,804,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,979,000Source | 5,067,000Source | 2,947,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,354,000Source | 1,004,000Source | 821,000Source |
| Other Assets, NoncurrentUSD | 13,809,000Source | 12,856,000Source | 7,276,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 141,496,000Source | 57,510,000Source | 43,815,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 5,000Source | 4,000Source | — |
| Additional Paid in CapitalUSD | 1,007,331,000Source | 699,651,000Source | 4,645,000Source |
| Retained Earnings (Accumulated Deficit)USD | -765,128,000Source | -387,391,000Source | -230,403,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -64,000Source | 194,000Source | 37,000Source |
| Stockholders' Equity Attributable to ParentUSD | 242,144,000Source | 312,458,000Source | -225,721,000Source |
| Liabilities and EquityUSD | 383,640,000Source | 369,968,000Source | 68,180,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 62,649,000Source | 57,292,000Source | 23,258,000Source |
| Operating Lease, Liability, CurrentUSD | 1,115,000Source | 785,000Source | 556,000Source |
| Accounts Payable, CurrentUSD | 7,111,000Source | 17,136,000Source | 5,396,000Source |
| Operating Lease, Liability, NoncurrentUSD | 211,000Source | 218,000Source | 257,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 54,423,000Source | 39,371,000Source | 17,306,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 360,500,000Source | 350,800,000Source | — |
| Deferred Tax Liabilities, NetUSD | 1,060,000Source | 563,000Source | 200,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 78,636,000Source | — | — |
| Short-term InvestmentsUSD | 232,551,000Source | 31,024,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 26,347,000Source | 10,821,000Source | 3,495,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | -10,043,000Source | 11,740,000Source | -418,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -172,333,000Source | -119,674,000Source | -30,529,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -251,886,000Source | -30,552,000Source | -17,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 18,000Source | 131,000Source | 17,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 215,280,000Source | 412,958,000Source | 20,116,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -209,191,000Source | 262,889,000Source | -10,352,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 110,641,000Source | 319,832,000Source | 56,943,000Source |
| Supplemental disclosure of cash flow information: | |||
| Income Taxes Paid, NetUSD | 15,000Source | — | — |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 26,347,000Source | 10,821,000Source | 3,495,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 360,500,000Source | 350,800,000Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | — |
| DepreciationUSD | 56,000Source | 137,000Source | 113,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -107,000Source | — | — |
| General and Administrative ExpenseUSD | 53,322,000Source | 29,749,000Source | 17,114,000Source |
| Income Tax Expense (Benefit)USD | -79,000Source | 429,000Source | 301,000Source |
| InterestExpenseNonoperatingUSD | 7,327,000Source | — | — |
| Investment Income, InterestUSD | 12,151,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -377,737,000Source | -156,988,000Source | -37,124,000Source |
| Nonoperating Income (Expense)USD | 5,241,000Source | 7,329,000Source | 324,000Source |
| Operating ExpensesUSD | 393,057,000Source | 168,888,000Source | 87,147,000Source |
| Other Nonoperating Income (Expense)USD | 417,000Source | 8,175,000Source | 624,000Source |
| Payments to Acquire InvestmentsUSD | 417,755,000Source | 36,421,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 4,096,000Source | 275,000Source | 116,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 10,000,000Source | 5,000,000Source | 50,000,000Source |
| Operating Income (Loss)USD | -383,057,000Source | -163,888,000Source | -37,147,000Source |
| Other Nonoperating Income (Expense)USD | 417,000Source | 8,175,000Source | 624,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -377,816,000Source | -156,559,000Source | -36,823,000Source |
| Income Tax Expense (Benefit)USD | -79,000Source | 429,000Source | 301,000Source |
| Net Income (Loss) Attributable to ParentUSD | -377,737,000Source | -156,988,000Source | -37,124,000Source |
| Earnings Per Share, BasicUSD per share | -8.44Source | -11.89Source | -24.25Source |
| Earnings Per Share, DilutedUSD per share | -8.44Source | -11.89Source | -24.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 44,730,052Source | 13,198,960Source | 1,531,178Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 44,730,052Source | 13,198,960Source | 1,531,178Source |
| Interest Expense (non-operating)USD | 7,327,000Source | — | — |
| Additional Financial Items | |||
| Current Income Tax Expense (Benefit)USD | -79,000Source | 429,000Source | 301,000Source |
| General and Administrative ExpenseUSD | 53,322,000Source | 29,749,000Source | 17,114,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -388,509,000Source | -160,918,000Source | -10,845,000Source |
| Investment Income, InterestUSD | 12,151,000Source | — | — |
| Nonoperating Income (Expense)USD | 5,241,000Source | 7,329,000Source | 324,000Source |
| Operating ExpensesUSD | 393,057,000Source | 168,888,000Source | 87,147,000Source |
| Research and Development ExpenseUSD | 168,063,000Source | 139,139,000Source | 60,033,000Source |
Offerings
Registration 333-298895
Filing attachments
tm2627406d1_ex99-1.htm · 8-K · 2026-10-13
Exhibit 99.1 Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease | Source: Zenas BioPharma Share – Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxic…
Read attachment ↗tm2624811d3_ex4-4.htm · S-8 · 2026-09-11
Exhibit 4.4 ZENAS BIOPHARMA, INC. 2026 INDUCEMENT PLAN First Amendment Pursuant to Section 9 of the Zenas BioPharma, Inc. 2026 Inducement Plan (the “Plan”), Zenas BioPharma, Inc. (the “Company”), by authorization of the Company’s Board of Directors, hereby amends the Plan as follows, effective as of August 5, 2026: Section 4(a)(i) of the Plan is hereby replaced in its entirety with the following text: “(a) Number of Shares. (i) Subject to adjustment as provided in Section 7…
Read attachment ↗tm2622871d1_ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 tm2622871d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared to prefilled syringes - - Obexelimab global Phase 2 SunStone SLE trial topline results expected in Q4 2026 - - ZB021 (ora…
Read attachment ↗tm2614295d1_ex99-1.htm · 8-K · 2026-05-13
EX-99.1 2 tm2614295d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results - - Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 - - Obexelimab global Phase 2 SunStone SLE trial enrollmen…
Read attachment ↗tm2610711d1_ex4-1.htm · 8-K · 2026-03-31
EX-4.1 4 tm2610711d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 ZENAS BIOPHARMA, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 31, 2026 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. …
Read attachment ↗tm2610711d1_ex4-2.htm · 8-K · 2026-03-31
EX-4.2 5 tm2610711d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 Zenas BioPharma, INC. and U.S. Bank Trust Company, National Association as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of March 31, 2026 2.50% Convertible Senior Notes due 2032 CROSS REFERENCE TABLE* Trust Indenture Indenture Section Act Section 310(a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) N/A (a)(5) N/A (b) N/A (c) …
Read attachment ↗